{"page":{"totalFilteredElements":16},"studies":[{"active":true,"description":"A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator&#8217;s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma","eudractNumber":"2023-510322-32","id":9816,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-02T12:28:02+02:00","shortTitle":"MERUS MCLA-158-CL02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A Phase I clinical trial to assess safety and tolerability of autologous ROR1 CAR-T cells in ROR1+ tumors","eudractNumber":"2024-512019-36","id":10837,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"ROR 1","id":"mt_288"}],"nctNumber":null,"phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2025-04-09T12:48:20+02:00","shortTitle":"NCT-Studie: LION 1","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"Nivolumab in combination with cisplatin and 5-flurouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma","eudractNumber":"2021-006477-32","id":7476,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT06019130","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-05-17T13:04:53+02:00","shortTitle":"NPC-Nivo","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases","eudractNumber":"2024-519929-38-00","id":11431,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT06856837","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-11-19T09:41:39+01:00","shortTitle":"Quintis","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)</p><p class=\"MsoNormal\"><b>CA057-001</b></p>","eudractNumber":"2023-509859-13","id":10285,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05519085","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-13T15:17:15+01:00","shortTitle":"SUCCESSOR-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"<div>INTERNATIONAL EURO EWING TRIAL FOR TREATMENT OPTIMISATION IN PATIENTS WITH EWING SARCOMA</div>","eudractNumber":"2019-004153-93","id":9005,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-12-04T08:17:19+01:00","shortTitle":"i EuroEwing","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]}]}